The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia
Open accessAbstract
CONTEXT: Cannabis use is associated with both impaired cognitive functions, including working memory, and an increased risk of schizophrenia. Schizophrenia is characterized by impairments in working memory that are associated with reduced gamma-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex. The cannabinoid 1 receptor (CB1R) is highly expressed in the dorsolateral prefrontal cortex, is contained in the axon terminals of a subpopulation of perisomatic-targeting GABA neurons, and, when activated, suppresses the release of GABA. OBJECTIVE: To determine the potential relationship between CB1R signaling and altered GABA neurotransmission in schizophrenia by evaluating CB1R messenger RNA (mRNA) and protein expression in the dorsolateral prefrontal cortex. DESIGN: In situ hybridization and immunocytochemistry techniques were used to examine the cortical levels of CB1R mRNA and protein, respectively. SETTING: Brain specimens were obtained from autopsies conducted at the Allegheny County Medical Examiner's Office, Pittsburgh, Pennsylvania. PARTICIPANTS: Postmortem brain specimens from 23 pairs of subjects with schizophrenia and age-, sex-, and postmortem interval-matched comparison subjects, as well as brain specimens from 18 macaque monkeys with long-term exposure to haloperidol, olanzapine, or placebo. MAIN OUTCOME MEASURES: Optical density measures of CB1R mRNA expression and protein levels and correlations with previously reported glutamic acid decarboxylase 67 and cholecystokinin mRNA measures. RESULTS: Levels of CB1R mRNA were significantly lower by 14.8% in the subjects with schizophrenia. Similarly, CB1R protein levels, assessed by radioimmunocytochemistry and standard immunocytochemistry, were significantly decreased by 11.6% and 13.9%, respectively. Group differences in CB1R mRNA levels were significantly correlated with those in glutamic acid decarboxylase 67 and cholecystokinin mRNA levels. Expression of CB1R mRNA was not changed in antipsychotic-exposed monkeys, and neither CB1R mRNA levels nor protein levels were affected by potential confounding factors in the subjects with schizophrenia. CONCLUSIONS: This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Self-citationCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Self-citationMarsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“Finally, long-term users of cannabis exhibit deficits in cognitive functions, such as working memory,(13) that are impaired in schizophrenia.(14) Working memory processes depend on the circuitry of the dorsolateral prefrontal cortex (DLPFC), andalterations in thisbrain region appear to contribute to working memory imp…”
Gamma Oscillations Correlate with Working Memory Load in Humans
Howard, M. W. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg084 · Cited by 766
Cited by
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Hashimoto, T., Arion, D., Unger, T., Maldonado-Avilés, J. G., Morris, H. M., Volk, D. W., Mirnics, K., & Lewis, D. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002011 · Cited by 490
Self-citationAyalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E., Breier, A., Shekhar, A., Amdur, R., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 397
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
Curley, A. A., Arion, D., Volk, D. W., Asafu-Adjei, J. K., Sampson, A. R., Fish, K. N., & Lewis, D. A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010052 · Cited by 283
Self-citationSubstance Use Disorders in Schizophrenia--Clinical Implications of Comorbidity
Volkow, N. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp016 · Cited by 273
Alterations in cortical interneurons and cognitive function in schizophrenia
Dienel, S. J., & Lewis, D. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.020 · Cited by 272
Self-citationAdolescent cannabis use and psychosis: epidemiology and neurodevelopmental models
Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237
Rethinking schizophrenia in the context of normal neurodevelopment
Catts, V. S., Fung, S. J., Long, L. E., Joshi, D., Vercammen, A., Allen, K. M., Fillman, S. G., Rothmond, D. A., Sinclair, D., Tiwari, Y., et al. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00060 · Cited by 206
Zamberletti, E., Beggiato, S., Steardo, L., Prini, P., Antonelli, T., Ferraro, L., Rubino, T., & Parolaro, D. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.028 · Cited by 147
Cortical basket cell dysfunction in schizophrenia
Curley, A. A., & Lewis, D. A. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.224659 · Cited by 136
Self-citationMaldonado-Avilés, J. G., Curley, A. A., Hashimoto, T., Morrow, A. L., Ramsey, A. J., O’Donnell, P., Volk, D. W., & Lewis, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08101484 · Cited by 91
Self-citationGlausier, J. R., Kimoto, S., Fish, K. N., & Lewis, D. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.010 · Cited by 53
Self-citationWędzony, K., & Chocyk, A. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70161-6 · Cited by 50
Differential gene expression in migratory streams of cortical interneurons
Antypa, M., Faux, C., Eichele, G., Parnavelas, J. G., & Andrews, W. D. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07896.x · Cited by 49
Metadata
- Authors
- Eggan, S. M., Hashimoto, T., & Lewis, D. A.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2008-07-07
- Volume
- 65
- Issue
- 7
- Pages
- 772
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2169890964
- Cited by
- 219
- References
- 15
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.